1.This Act may be cited as the
Endocrine-Disrupting Chemicals
Exposure Elimination Act of 2011
.
2.The table of contents
of this Act is as follows:
Sec. 1. Short title.
Sec. 2. Table of contents.
Sec. 3. Findings.
Sec. 4. Definitions.
Sec. 5. Tiering applicable to levels of evidence and
concern.
Title I—Research on endocrine-disrupting chemicals
Sec. 101. National toxicology program activities.
Sec. 102. Research program of national institute of
environmental health sciences.
Title II—Reducing exposure to endocrine-disrupting
chemicals
Sec. 201. Federal agency action.
Sec. 202. Citizen suits.
Title III—Training
Sec. 301. Training in fields related to the prevention of
endocrine disruption.
Title IV—Miscellaneous
Sec. 401. Authorization of appropriations.
3.Congress finds that—
(1)there is growing
evidence that the human endocrine system is extremely sensitive to particular
chemicals;
(2)numerous studies
show links between particular chemicals and hormone functions in both animals
and humans, and those links have been further connected to numerous
disorders;
(3)a
research and evaluation program that targets suspected endocrine-disrupting
chemicals would establish greater scientific certainty with respect to the
linkage of particular chemicals with endocrine system effects;
(4)credible linkages
established by the research described in paragraph (3) would establish a basis
for regulation under authorities that include—
(A)the
Federal Insecticide, Fungicide, and Rodenticide
Act (7 U.S.C. 136 et seq.);
(B)the Food Quality
Protection Act of 1996 (7 U.S.C. 136 note; Public Law 104–170);
(C)the
Toxic Substances Control Act (15
U.S.C. 2601 et seq.);
(D)the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 301 et seq.);
(E)the
Federal Water Pollution Control Act
(33 U.S.C. 1251 et seq.);
(F)the Safe Drinking
Water Act (42 U.S.C. 300f et seq.); and
(G)the
Clean Air Act (42 U.S.C. 7401 et
seq.);
(5)the research
described in paragraph (3), as well as availability of information and the
scientific perspective derived from that research, would promote voluntary
actions to reduce exposure to those harmful endocrine-disrupting chemicals
through market forces;
(6)there is a need to
educate the public on the results of research on endocrine-disrupting chemicals
so that manufacturers, processors, retailers, and individual consumers can make
informed decisions about potential exposure to harmful chemicals;
(7)people should be
protected from chemicals that are found to have endocrine-disrupting effects;
and
(8)animal testing should be reduced to the
minimum necessary with the goal of transitioning to a predominantly nonanimal
paradigm as articulated in the 2007 National Research Council report entitled
Toxicity Testing in the Twenty-First Century: A Vision and a
Strategy
.
4.In this Act:
(1)The
term chemical means an individual chemical, a combination of
chemicals, or a mixture of chemicals.
(2)The
term Director means the Director of the National Institute of
Environmental Health Sciences.
(3)Endocrine-disrupting
chemicalThe term endocrine-disrupting chemical
means a chemical that interrupts, alters, interferes with, disturbs, or
otherwise changes the human endocrine system or cell functioning.
(4)Endocrine
disruption expert panel; expert panel; panelThe terms
endocrine disruption expert panel, expert panel, and
panel mean the endocrine disruption expert panel established under
section 101(a)(2).
5.Tiering
applicable to levels of evidence and concernIn identifying, determining, or making a
finding with respect to a level of evidence or a level of concern under this
Act (including under sections 101(a)(3), 101(a)(4), 101(b)(2)(C), and
201(a)(2)(B)), the Director or the expert panel, as applicable, shall select
from among the following levels:
(1)High.
(2)Substantial.
(3)Minimal.
(4)None.
<enum>I</enum><header>Research on
endocrine-disrupting chemicals</header>
<section id="H3C764B8AEB4544788BAC1FDFDE6AA02C"><enum>101.</enum><header>National
toxicology program activities</header>
<subsection id="H88385261ECD542AE94AE65BD4577D9BC"><enum>(a)</enum><header>In
general</header><text display-inline="yes-display-inline">As part of the
National Toxicology Program, the Director, in consultation with the National
Toxicology Program Board of Scientific Counselors (or any successor board or
committee), shall—</text>
<paragraph id="H31107E95EFF2409D9FC8508FD06E10B0"><enum>(1)</enum><text display-inline="yes-display-inline">establish and implement a research program
designed to strengthen the scientific basis of information used by Federal
agencies to understand the effects of, and reduce human exposure to,
endocrine-disrupting chemicals;</text>
</paragraph><paragraph id="HBC7E47D00F8A4F7BBCBDC60EFAA31BDE"><enum>(2)</enum><text>subject to
subsection (b)(1), establish an endocrine disruption expert panel and direct
the panel to consider and report to the Director on issues relating to the
identification, classification, or evaluation of endocrine-disrupting chemicals
under subsection (b)(2);</text>
</paragraph><paragraph id="H0961C2D72D5B416CA62D2034B5079EA4"><enum>(3)</enum><text>for each chemical
determined by the Director to be a potential or actual endocrine-disrupting
chemical identify—</text>
<subparagraph id="H1D00218F63FA42E6AD08FF685AE10C2D"><enum>(A)</enum><text>the level of
evidence that the chemical is or may be an endocrine-disrupting
chemical;</text>
</subparagraph><subparagraph id="H94D3FA4081F74BDDB2BE768E32A6BE8A"><enum>(B)</enum><text>the level of
concern that the chemical may disrupt the human endocrine system; and</text>
</subparagraph><subparagraph id="H3D55978041E24C8A973755AA140E4498"><enum>(C)</enum><text>the pathways of
exposure to the chemical for humans and animals; and</text>
</subparagraph></paragraph><paragraph id="H1D26E810DECE4803A97808840A7C22E8"><enum>(4)</enum><text>not later than 2
years after the date of enactment of this Act and every 2 years thereafter,
make publicly available and submit to Congress and each relevant Federal
agency—</text>
<subparagraph id="H5D7F5AEFCC7349EBA900771F0E8F42AC"><enum>(A)</enum><text>an up-to-date list
that—</text>
<clause id="id600D581B61934B43AAE271CA96C8202C"><enum>(i)</enum><text>specifies each
chemical identified by the Director to be a potential or actual
endocrine-disrupting chemical; and</text>
</clause><clause id="id1EB2BB0EC63E417FB9AE5725EA5468CB"><enum>(ii)</enum><text>identifies—</text>
<subclause id="idA43FE0C5EC6F4C52827506260AA1F8FB"><enum>(I)</enum><text>the level of
evidence that the chemical disrupts the human endocrine system;</text>
</subclause><subclause id="id9710B5F57F1E409C8394BFD891DEFC0D"><enum>(II)</enum><text>the level of
concern that the chemical disrupts the human endocrine system; and</text>
</subclause><subclause id="idC250B019F7F545089C9B419349861B2D"><enum>(III)</enum><text>the pathways of
exposure to the chemical for humans and animals; and</text>
</subclause></clause></subparagraph><subparagraph id="HF308140CA1674E289C37610E7A1A9DBB"><enum>(B)</enum><text>a report
on—</text>
<clause id="HA4CEFBE0E4D54BE1A84BA30FE13EDFA3"><enum>(i)</enum><text>the
activities of the National Toxicology Program pertaining to
endocrine-disrupting chemicals; and</text>
</clause><clause id="H11764971DBB1426683B1D3ED45EE28A1"><enum>(ii)</enum><text>the
activities of Federal agencies with respect to endocrine-disrupting chemicals,
including actions taken or expected to be taken pursuant to section 201.</text>
</clause></subparagraph></paragraph></subsection><subsection id="HC593E492070C422496BB37AE8A995C74"><enum>(b)</enum><header>Expert
panel</header>
<paragraph id="HAEA6D24A31FC4CAFAB6EFA5E4EB43DB6"><enum>(1)</enum><header>Appointment</header><text display-inline="yes-display-inline">The Director, in consultation with the
National Toxicology Program Board of Scientific Counselors (or any successor
board or committee), shall appoint the members of the endocrine disruption
expert panel from among individuals who—</text>
<subparagraph id="HECD7A5D0A960410B92573E4A6CF33204"><enum>(A)</enum><text display-inline="yes-display-inline">have established expertise in the field of
endocrine disruption research by publishing research in peer-reviewed
literature;</text>
</subparagraph><subparagraph id="idAEE81C894A4947519D1F0BE96017FDB9"><enum>(B)</enum><text display-inline="yes-display-inline">have received Federal endocrine
research-related funding during the 2 years preceding the date of appointment
under this subsection;</text>
</subparagraph><subparagraph id="H7861A3BCBAFB4A0FAEB1FBC3A06C5D2D"><enum>(C)</enum><text>provide assurances
that the member will carry out the duties of that member in a manner free of
conflicts of interest, as determined by the Director, including by complying
with section 208 of title 18, United States Code; and</text>
</subparagraph><subparagraph id="HA58242652435403E940AA6B38056E60E"><enum>(D)</enum><text>represent diverse
disciplines, which may include endocrinology, developmental and neurological
biology, embryology, biochemistry, physiology, epidemiology, endocrine-driven
oncology, in vitro and computational toxicology, and medical research.</text>
</subparagraph></paragraph><paragraph id="H49C11D7FBEF84E25961146785933E5A4"><enum>(2)</enum><header>Duties</header><text>For
each of the 10 fiscal years following the date of enactment of this Act, the
expert panel shall—</text>
<subparagraph id="H630A6AC2F575429C8D69B4385861A4D3"><enum>(A)</enum><text>consider and
report to the Director on issues relating to the identification,
classification, or evaluation of not more than 10 endocrine-disrupting
chemicals or groups of endocrine-disrupting chemicals;</text>
</subparagraph><subparagraph commented="no" id="HC88E705F86A147BFAB59D8124D54D966"><enum>(B)</enum><text>evaluate existing
research aimed at understanding the biological pathways in humans by which
endocrine-disrupting chemicals operate and as appropriate, identify future
research priorities; and</text>
</subparagraph><subparagraph commented="no" id="H58E450AC518D469C84F01DF07783C100"><enum>(C)</enum><text>maintain a list
that identifies chemicals of concern for endocrine disruption effects,
including findings based on peer-reviewed studies and other relevant data that
relate to—</text>
<clause commented="no" display-inline="no-display-inline" id="H3745652012924B8A9E75D28C6983D6B0"><enum>(i)</enum><text>whether a chemical
is a potential or actual endocrine-disrupting chemical;</text>
</clause><clause commented="no" id="H39280DAC5BDC47908ED747BB558C91FF"><enum>(ii)</enum><text>the level of
evidence that the chemical is or may be an endocrine-disrupting
chemical;</text>
</clause><clause commented="no" id="HDD641281C640487AACE00B555CBFCA69"><enum>(iii)</enum><text>the level of
concern that the chemical may disrupt the human endocrine system;</text>
</clause><clause commented="no" id="HD13304C1893D425881C8E2FF2BD959FE"><enum>(iv)</enum><text>the pathways of
exposure to the chemical for humans and animals; and</text>
</clause><clause commented="no" id="H6C707F3298084075AEF30B43E684A5B8"><enum>(v)</enum><text>the need for
additional data, assays, testing, or research to determine the level of concern
associated with the potential of the chemical to disrupt the human endocrine
system.</text>
</clause></subparagraph></paragraph><paragraph commented="no" id="H777A81446E784DB8B7519732B92BC0F9"><enum>(3)</enum><header>Report</header><text display-inline="yes-display-inline">The expert panel shall submit to the
Director and make publicly available a biennial report on the activities of the
panel, including an up-to-date version of the list under paragraph
(2)(C).</text>
</paragraph></subsection><subsection id="HA6DE6E62F0A84371B5F216CCC3F963B6"><enum>(c)</enum><header>Petitions</header>
<paragraph id="H965870DC9289499081C8398CF64C08A5"><enum>(1)</enum><header>In
general</header><text>Any Federal agency, State, local, or tribal government,
or person may petition the Director—</text>
<subparagraph id="H7DF9B354C0824154979668D02090CC53"><enum>(A)</enum><text>to determine
whether a chemical should be identified by the National Toxicology Program to
be a potential or actual endocrine-disrupting chemical and included in the list
under subsection (a)(4)(A); or</text>
</subparagraph><subparagraph id="H8421C513F08C410E8B4BC4CD6A672E19"><enum>(B)</enum><text>to reclassify a
chemical, revise a finding, or amend any other determination of the National
Toxicology Program based on new information.</text>
</subparagraph></paragraph><paragraph id="H00CB45EAB0D34B0FA36C28A6497C1699"><enum>(2)</enum><header>Rules</header><text>The
Director shall adopt rules that provide for—</text>
<subparagraph id="H2D73048B04BB49CBA59E7FB421FFA28E"><enum>(A)</enum><text>the form and
procedure for filing a petition under paragraph (1); and</text>
</subparagraph><subparagraph id="H44054ADC114E444982ECD4F5BF28CAB9"><enum>(B)</enum><text>the procedural
rights of an entity that files a petition under paragraph (1).</text>
</subparagraph></paragraph></subsection><subsection id="HBE2D8B5E32934445AFB809C94EBBFBCD"><enum>(d)</enum><header>No judicial
review</header><text>A listing, finding, or other determination under this
section shall not be subject to—</text>
<paragraph id="id947C3AD2F510400FAC4BA97238C1FF64"><enum>(1)</enum><text>judicial review;
or</text>
</paragraph><paragraph id="id13C1AFC78E794D43A7B3544DBB103041"><enum>(2)</enum><text>correction under
section 515 of the Treasury and General Government Appropriations Act, 2001
(114 Stat. 2763A–153).</text>
</paragraph></subsection></section><section id="H76D7CA59B0A74FD69E6EA754719DB128"><enum>102.</enum><header>Research
program of national institute of environmental health sciences</header><text display-inline="no-display-inline">Subpart 12 of part C of title IV of the
Public Health Service Act (42 U.S.C. 281 et seq.) is amended by adding at the
end the following:</text>
<quoted-block display-inline="no-display-inline" id="idA576F55665E642629E03C21B16C6C7A7" style="OLC">
<section id="H31A7693FD1B04945970D0FC3BED4F626"><enum>463C.</enum><header>Endocrine
disruption research program</header>
<subsection id="H33A6C9BB92DC4D2E9F5E119E95A7A453"><enum>(a)</enum><header>Definitions</header><text display-inline="yes-display-inline">In this section:</text>
<paragraph commented="no" id="H43A7B6635C154E3E91FE374EF764DD5F"><enum>(1)</enum><header>Chemical</header><text display-inline="yes-display-inline">The term <term>chemical</term> means an
individual chemical, a combination of chemicals, or a mixture of
chemicals.</text>
</paragraph><paragraph id="H424DA6E7FF3F4B47B28FE3F1E6C2F005"><enum>(2)</enum><header>Endocrine-disrupting
chemical</header><text>The term <term>endocrine-disrupting chemical</term>
means a chemical that interrupts, alters, interferes with, disturbs, or
otherwise changes the human or animal endocrine system or its
functioning.</text>
</paragraph></subsection><subsection id="id5F0A36920F144150BAF7281911A10DA1"><enum>(b)</enum><header>Endocrine
Disruption Research Program</header>
<paragraph id="id81D3BBAD565745BD8C14F33EAF54997A"><enum>(1)</enum><header>In
general</header><text display-inline="yes-display-inline">The Director of the
Institute shall conduct and support a research program, to be known as the
<quote>Endocrine Disruption Research Program</quote>, to improve the
understanding of the manner in which chemicals can disrupt the human endocrine
system.</text>
</paragraph><paragraph id="id9CC00FB27E3E49A495B8E93FEA78734C"><enum>(2)</enum><header>Contents</header><text display-inline="yes-display-inline">The Endocrine Disruption Research Program
shall—</text>
<subparagraph id="HD76300FFB16E40F4974442C6E0DC6FDA"><enum>(A)</enum><text>be
designed—</text>
<clause id="H0D743D6C5BB24621A5939AE52DB62F51"><enum>(i)</enum><text display-inline="yes-display-inline">to develop the information needed by
Federal agencies to understand chemical disruption of the endocrine system and
reduce human and animal exposure to endocrine-disrupting chemicals;</text>
</clause><clause id="H162FFDF09CE545B9A5EFE62339C9E0D1"><enum>(ii)</enum><text>to understand the
cellular pathways in humans by which endocrine-disrupting chemicals are able to
cause adverse effects; and</text>
</clause><clause id="HAC83BE2F849A43B5920BD6CE40647B0A"><enum>(iii)</enum><text>to use
laboratory practices that will produce data that are sufficiently accurate and
reproducible to be used for regulatory decisions;</text>
</clause></subparagraph><subparagraph id="HE33934AD2A2A4036AB71DC6424AF107B"><enum>(B)</enum><text>include research
to design, develop, and validate appropriately sensitive tests to screen and
identify chemicals capable of disrupting the human endocrine system;</text>
</subparagraph><subparagraph id="HC3F79EC0FE1F4C8987F6E5E57DB3948B"><enum>(C)</enum><text>address the full
range of potential human health impacts, including—</text>
<clause id="H4FA6F3FDB66A4E06B0B30D8EDB8D98C1"><enum>(i)</enum><text>male and female
developmental and reproductive disorders;</text>
</clause><clause id="H47885846FBE44BC98F450621F77E578D"><enum>(ii)</enum><text display-inline="yes-display-inline">brain and neurobehavioral disorders;</text>
</clause><clause id="HE4FDAE3A2EF94582BA912AA27BAE5D0D"><enum>(iii)</enum><text>metabolic
syndromes, prediabetes, diabetes, improper glucose and fat metabolisms,
obesity, and cardiovascular disorders;</text>
</clause><clause id="H31236CAFC8F547018E8EA04D2363CFBF"><enum>(iv)</enum><text>effects on the
pituitary, hypothalamus, hippocampus, thyroid, adrenal system, immune system,
bones, cardiovascular system, and other endocrine organs and systems throughout
all life stages;</text>
</clause><clause id="H982865E35D604F77BC2FDAB99667DFDE"><enum>(v)</enum><text>hormonally driven
cancer; and</text>
</clause><clause id="H90CD135F4D2C4D26A3B7158CC44CED93"><enum>(vi)</enum><text>other related
effects;</text>
</clause></subparagraph><subparagraph id="H78390A69AE35473A93587C054836F945"><enum>(D)</enum><text>consider the
potential for additive and synergistic effects;</text>
</subparagraph><subparagraph id="H6FB77E94A77349AB942E75A068182829"><enum>(E)</enum><text>be carried out
using a multidisciplinary approach to ensure connections among multiple levels,
including the molecular, organ, and whole animal or human levels;</text>
</subparagraph><subparagraph id="HB9BC8FDECEF64E2EBB7C6E9DDD44E194"><enum>(F)</enum><text>refine
computational modeling tools to integrate cellular pathway data into a
dose-response framework for risk assessment;</text>
</subparagraph><subparagraph id="H93B1C2964C734DE5B7C07BF855391B47"><enum>(G)</enum><text>identify
biomarkers of exposure and effect that can be further developed and translated
for use in human epidemiological and public health studies focused on defining
the role of endocrine-disrupting chemicals in disease etiology across the
lifespan; and</text>
</subparagraph><subparagraph id="HA28A7CCBE246422BACA0800E7A80FCB8"><enum>(H)</enum><text>ensure that
research or testing involving living animals is carried out only when equally
effective and reliable alternative approaches for obtaining the result sought
are not readily available.</text>
</subparagraph></paragraph></subsection><subsection id="HD61B482EC5024BA5B8A336BB4003BAE5"><enum>(c)</enum><header>Workshops and
forums</header><text>The Director of the Institute may conduct workshops and
forums and provide information on the health effects associated with chemicals
that may disrupt the endocrine system—</text>
<paragraph id="H23A1C21B9F3A4AE68AAB13E78F5D2B08"><enum>(1)</enum><text>to identify
chemicals for research under subsection (b);</text>
</paragraph><paragraph id="H1B6EC03310C24D6FBE269BC2CE73C217"><enum>(2)</enum><text>to strategize on
approaches for the development of sensitive tests to screen chemicals for
endocrine-disrupting activity using assays;</text>
</paragraph><paragraph id="HF3E2EA31C36541A3AA6362ED40961237"><enum>(3)</enum><text>to review the
state of the science on endocrine-disrupting chemicals and provide
recommendations for a research, testing, and training agenda; and</text>
</paragraph><paragraph id="H83D88A6DDD5D47BDADBD0C9646049B07"><enum>(4)</enum><text>to educate
attendees about endocrine-disrupting
chemicals.</text>
</paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
</section><enum>II</enum><header>Reducing exposure
to endocrine-disrupting chemicals</header>
<section id="H07351E16F331496E9F72B1D5CE59D3E4"><enum>201.</enum><header>Federal agency
action</header>
<subsection id="H7DEBC2B447A5419B8DCD6F217399108E"><enum>(a)</enum><header>Response to list
and strategy</header>
<paragraph id="H8F867771A75B4609A611E7FB542CBEC6"><enum>(1)</enum><header>In
general</header><text>Not later than 90 days after receiving each biennial
list, strategy, and report under section 101(a)(4), each Federal agency with
regulatory authority over any chemical included on the list shall prepare and
publish a written response to the list and strategy.</text>
</paragraph><paragraph id="HC25D5B431012496EB6F3810F41D256B7"><enum>(2)</enum><header>Contents</header><text>At
a minimum, the response of a Federal agency under paragraph (1) shall—</text>
<subparagraph id="H60A4671C7A0A4AAD883A6DFA2A6564DB"><enum>(A)</enum><text>include an
evaluation of the findings and determinations of the National Toxicology
Program pertaining to each listed chemical subject to the regulatory authority
of that Federal agency; and</text>
</subparagraph><subparagraph id="HA0BDE44100D340C4A65EE3AF1D40E384"><enum>(B)</enum><text>adopt or modify,
as scientifically appropriate, each finding of the National Toxicology Program
pertaining to—</text>
<clause id="H806F260570934F3496621E58AF8F4BDB"><enum>(i)</enum><text display-inline="yes-display-inline">whether the chemical disrupts or may
disrupt the human endocrine system;</text>
</clause><clause id="H8B4D782C57684476BAA959567DD42FED"><enum>(ii)</enum><text>the
level of concern associated with the potential of the chemical to disrupt the
human endocrine system; and</text>
</clause><clause id="H4622808D8E8D4151B5B857D762A0367A"><enum>(iii)</enum><text>the pathways of
exposure to the chemical for humans and animals.</text>
</clause></subparagraph></paragraph></subsection><subsection id="HCF2A98E1A4554B0C884A9BA78E2843CB"><enum>(b)</enum><header>Minimal level of
concern</header><text>If the Director finds under section 101(a)(3)(A) that
there is at least a minimal level of concern that a chemical may disrupt the
human endocrine system each Federal agency with regulatory authority over the
chemical shall—</text>
<paragraph id="H279BFA6B9F164ABD8C21EFAED0BF9DAD"><enum>(1)</enum><text>develop a strategy
for reducing human exposure to the chemical that—</text>
<subparagraph id="H8A910ABB1E3140ED9C466E58F80E88A2"><enum>(A)</enum><text>is made publicly
available not later than 180 days after the date on which the agency receives
the finding of the Director; and</text>
</subparagraph><subparagraph id="H7B54FC2B3D844429B317D5FEDF7EE728"><enum>(B)</enum><text>includes methods
to promote voluntary actions by industry for reducing human exposure to the
chemical; and</text>
</subparagraph></paragraph><paragraph id="H5C3FF0A618F14309B6BF3985F90DF245"><enum>(2)</enum><text>take any necessary
action under that regulatory authority, including further testing or issuance
of orders, regulations, or public notices, to reduce or eliminate human
exposure to the chemical.</text>
</paragraph></subsection><subsection id="H25B58E4FFE764C4BBFBDCC5EE843EDA7"><enum>(c)</enum><header>Highest level of
concern</header>
<paragraph id="H95CC2F2F5A0A4572915EADE849579B94"><enum>(1)</enum><header>Prohibition</header><text>Beginning
on the date that is 2 years after the date on which the Director makes publicly
available a finding under section 101(a)(3)(B) that there is a high level of
concern that a chemical may disrupt the human endocrine system, it shall be
unlawful to use the chemical in interstate commerce or in a manner that affects
interstate commerce, unless the pathway to human exposure is mitigated before
or in conjunction with that use.</text>
</paragraph><paragraph id="H6FEBA9B0750544458DE36BB131C64C1C"><enum>(2)</enum><header>Federal agency
action</header><text display-inline="yes-display-inline">Not later than the
date that is 2 years after the date on which the Director makes publicly
available a finding described in paragraph (1), each Federal agency with
regulatory authority over the chemical subject to the finding shall establish
regulations or take other appropriate actions to implement paragraph (1) with
respect to the chemical.</text>
</paragraph></subsection><subsection id="H6354161EB6A94E98AD482C7E7A5C83A6"><enum>(d)</enum><header>Aggregated
computational toxicology resources databases</header><text>The Administrator of
the Environmental Protection Agency shall include the findings and
determinations of the National Toxicology Program pertaining to
endocrine-disrupting chemicals in the Aggregated Computational Toxicology
Resource (ACToR) databases (or any successor databases) to the extent otherwise
permitted by law, including any restrictions on the disclosure of confidential
business information.</text>
</subsection></section><section id="HA8CE3CB8963B475DA551BC5EB5F2E76F"><enum>202.</enum><header>Citizen
suits</header>
<subsection id="HE79BBEB0C1A843CCB779C5E6EA4E0228"><enum>(a)</enum><header>Authority To
Bring Civil Actions</header><text>Any State, local, or tribal government, or
any other person, may commence a civil action to prevent or restrain a
prohibited use of a chemical in violation of section 201.</text>
</subsection><subsection id="H605926396D3D4270A00627E1C2E03FE4"><enum>(b)</enum><header>Jurisdiction</header><text>The
United States Court of Appeals for the circuit in which the person commencing
the civil action resides shall have exclusive original jurisdiction over an
action described in subsection (a).</text>
</subsection></section><enum>III</enum><header>Training</header>
<section id="H30CED2CD5E5546DDADEFCC60E3324B1D"><enum>301.</enum><header>Training in
fields related to the prevention of endocrine disruption</header><text display-inline="no-display-inline">The Director shall establish a program to
support, either directly or by making grants, graduate and postdoctoral
training in fields relating to the study and prevention of endocrine
disruption.</text>
</section><enum>IV</enum><header>Miscellaneous</header>
<section id="H7E9B7393C54C46A4966C10017FB627B2"><enum>401.</enum><header>Authorization
of appropriations</header><text display-inline="no-display-inline">There are
authorized to be appropriated to carry out this Act and the amendments made by
this Act such sums as are necessary for each of fiscal years 2012 through
2021.</text>
</section>